SCHEMBL389309

SCHEMBL389309

CC(C)OC(=O)N1CCC(C(=O)Nc2ccc(Br)cc2)CC1

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 2/20 0.57
PTPN2 P17706 1/20 0.57
PTPN6 P29350 1/20 0.57
LMNA P02545 2/20 0.57
HTT P42858 2/20 0.57
MAPT P10636 2/20 0.57
KMT2A Q03164 4/20 0.52
TDP1 Q9NUW8 2/20 0.52
FAAH O00519 1/20 0.52
EPHX2 P34913 1/20 0.52
MEN1 O00255 2/20 0.50
ABL1 P00519 1/20 0.50
RIN1 Q13671 1/20 0.50
POLB P06746 1/20 0.49
ALDH1A1 P00352 2/20 0.48
PKM P14618 1/20 0.48
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2378725 0.84 PTPN2 (0.81) PTPN1PTPN2PTPN6LMNAHTT
SCHEMBL10131252 0.78 LMNA (0.60) LMNAHTTMAPTKMT2ATDP1
SCHEMBL12771496 0.78 PTPN2 (0.72) PTPN1PTPN2PTPN6LMNAHTT
SCHEMBL16934608 0.78 GPR119 (0.54) HTTMAPTALDH1A1
SCHEMBL2719839 0.76 NAMPT (0.67) PTPN1LMNAHTTMAPTKMT2A
SCHEMBL865044 0.75 GPR119 (0.56) ALDH1A1
SCHEMBL867019 0.75 ALDH1A1 (0.52) KMT2AMEN1POLBALDH1A1
SCHEMBL23390136 0.75 LMNA (0.60) PTPN1PTPN2LMNAHTTKMT2A
SCHEMBL6525714 0.74 PTPN1 (0.77) PTPN1PTPN2PTPN6LMNAHTT
SCHEMBL2934441 0.74 SMN1; SMN2 (0.43) PTPN1PTPN2PTPN6LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120077812-A1 BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS FANG JING (US) 2012-03-29 US disclosed
US-8101634-B2 Bicyclic compounds and use as antidiabetics GLAXOSMITHKLINE LLC (US) 2012-01-24 US disclosed
EP-2325182-A1 Bicyclic compounds and use as antidiabetics Glaxosmithkline LLC (US) 2011-05-25 EP disclosed
US-20100029650-A1 BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS SMITH KLINE BEECHAM CORPORATION a corporation 2010-02-04 US disclosed
EP-2094683-A2 BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS SmithKline Beecham Corporation (US) 2009-09-02 EP disclosed
WO-2008070692-A2 BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS SMITHKLINE BEECHAM CORPORATION (US) 2008-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077812-A1 BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS GPR119, GOT2, PC PTPN1 4085/4885PTPN2 3234/4885PTPN6 3691/4885
US-20100029650-A1 BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS GPR119, GOT2, PC PTPN1 4085/4885PTPN2 3234/4885PTPN6 3691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.